Nemifitide Free Base | CAS# 173240-15-8 (free base) | antidepressant drug

MedKoo Cat#: 414315 | Name: Nemifitide Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nemifitide Free Base is a novel antidepressant drug with a pentapeptide structure similar to that of melanocyte-inhibiting factor and the amino acid sequence 4-F-Phe-4-OH-Pro-Arg-Gly-Trp-NH₂. It is under development by Tetragenex for the treatment of major depressive disorder.

Chemical Structure

Nemifitide Free Base

CAS#173240-15-8 (free base)

Theoretical Analysis

MedKoo Cat#: 414315

Name: Nemifitide Free Base

CAS#: 173240-15-8 (free base)

Chemical Formula: C33H43FN10O6

Exact Mass: 694.3351

Molecular Weight: 694.77

Elemental Analysis: C, 57.05; H, 6.24; F, 2.73; N, 20.16; O, 13.82

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

173240-15-8 (free base) 204992-09-6 (ditrifluate)

Synonym

Nemifitide Free Base

IUPAC/Chemical Name

(2S,4R)-N-((S)-1-((2-(((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-5-guanidino-1-oxopentan-2-yl)-1-((S)-2-amino-3-(4-fluorophenyl)propanoyl)-4-hydroxypyrrolidine-2-carboxamide

InChi Key

SGXPTOACEHQGHL-RCNLLYRESA-N

InChi Code

InChI=1S/C33H43FN10O6/c34-20-9-7-18(8-10-20)12-23(35)32(50)44-17-21(45)14-27(44)31(49)43-25(6-3-11-39-33(37)38)30(48)41-16-28(46)42-26(29(36)47)13-19-15-40-24-5-2-1-4-22(19)24/h1-2,4-5,7-10,15,21,23,25-27,40,45H,3,6,11-14,16-17,35H2,(H2,36,47)(H,41,48)(H,42,46)(H,43,49)(H4,37,38,39)/t21-,23+,25+,26+,27+/m1/s1

SMILES Code

N[C@H](C(N1C[C@@H](C[C@H]1C(N[C@H](C(NCC(N[C@H](C(N)=O)Cc(c[nH]2)c3c2cccc3)=O)=O)CCCNC(N)=N)=O)O)=O)Cc4ccc(F)cc4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 694.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Dingemanse J. Nemifitide. Innapharma. Curr Opin Investig Drugs. 2003 Jul;4(7):859-62. PMID: 14619408. 2: Overstreet DH, Hlavka J, Feighner JP, Nicolau G, Freed JS. Antidepressant- like effects of a novel pentapeptide, nemifitide, in an animal model of depression. Psychopharmacology (Berl). 2004 Sep;175(3):303-9. doi: 10.1007/s00213-004-1815-9. PMID: 14985919. 3: Montgomery SA, Feighner JP, Sverdlov L, Shrivastava RK, Cunningham LA, Kiev A, Hlavka J, Tonelli G. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder. Int J Neuropsychopharmacol. 2006 Oct;9(5):517-28. doi: 10.1017/S1461145705006139. Epub 2005 Oct 31. PMID: 16259645. 4: Nicolau G, Feighner JP, Stout R, Hlavka J, Gutierrez M, Ciric S, Freed J. Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers. Biopharm Drug Dispos. 2005 Dec;26(9):379-85. doi: 10.1002/bdd.470. PMID: 16130176. 5: Feighner JP, Sverdlov L, Nicolau G, Abajian HB, Hlavka J, Freed JS, Tonelli G Jr. Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment. Int J Neuropsychopharmacol. 2003 Sep;6(3):207-13. doi: 10.1017/S1461145703003481. PMID: 12974986. 6: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jul-Aug;29(6):427-37. PMID: 17922073. 7: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. PMID: 14988742. 8: Feighner JP, Nicolau G, Abajian H, Marricco NC, Morrison J, Sverdlov L, Hlavka J, Tonelli G Jr, Di Spirito C, Faria G. Clinical pharmacokinetic studies with INN 00835 (nemifitide), a novel pentapeptide antidepressant. Biopharm Drug Dispos. 2002 Jan;23(1):33-9. doi: 10.1002/bdd.290. PMID: 11891671. 9: Bayés M, Rabasseda X, Prous JR. Gateways to Clinical Trials. Methods Find Exp Clin Pharmacol. 2002 Sep;24(7):431-55. PMID: 12428432. 10: Holtzheimer PE, Nemeroff CB. Novel targets for antidepressant therapies. Curr Psychiatry Rep. 2008 Dec;10(6):465-73. doi: 10.1007/s11920-008-0075-5. PMID: 18980729; PMCID: PMC4413474.